Male Hypogonadism Market Report and Forecast 2024-2032

Male Hypogonadism Market Outlook

The male hypogonadism market size is expected to grow at a CAGR of 3.6% during the forecast period of 2024-2032, driven by the rising prevalence of male hypogonadism, growing elderly population size, and heightened awareness among patients across the 8 major markets.

Male Hypogonadism Market Overview 

Male hypogonadism is characterized by the low production of the male sex hormone testosterone, resulting in testosterone deficiency in the body. The prevalence of the condition is estimated to be 6% to 12% in the general population and is found to increase with age. It is reported that the prevalence rate of male hypogonadism is 40% in men having type 2 diabetes , suggesting a strong correlation between hypogonadism and type 2 diabetes. With the growing number of cases of testicular failure, the male hypogonadism market demand is projected to witness a surge in the forecast period.

The evolving regulatory frameworks characterised by surge in approvals from the health regulatory agencies are positively influencing the market growth. In October 2023, Eugia Pharma Specialities Limited, the subsidiary of Aurobindo Pharma , received its final approval from the United States Food and Drug Administration (FDA) to produce and commercialize Testosterone Cypionate injection. The product will be available in concentrations of 100 mg/mL and 200 mg/mL in multi-dose vials and 200 mg/mL in single-dose vials. The launch is scheduled for November 2023, and this is the 169th abbreviated new drug application (ANDA) approval received from Eugia Pharma Speciality Group (EPSG) facilities. Testosterone Cypionate injection is intended for replacement therapy in males with low or absent endogenous testosterone, such as primary hypogonadism.

The market is also driven by the growing geriatric population which is at a higher risk of developing male hypogonadism. In addition, the rising awareness among the patients coupled with investments and advancements in the healthcare sector will also fuel the market demand.

Male Hypogonadism Market Trends

Male Hypogonadism Market Segmentation

Market Breakup by Type

• Primary Hypogonadism

• Secondary Hypogonadism

The market is segmented by type into primary hypogonadism and secondary hypogonadism. Primary hypogonadism involves dysfunction of the testes whereas secondary hypogonadism occurs due to a dysfunction in the hypothalamus or pituitary gland.

Market Breakup by Diagnosis

• Blood Tests

• Imaging Scans

• Genetic Testing

• Clinical Evaluation

By diagnosis, the market is segmented into blood tests, imaging scans, genetic testing, and clinical evaluation. These diagnostic approaches help to determine appropriate treatment for individuals with hypogonadism.

Market Breakup by Therapy

• Testosterone Replacement Therapy

• Selective Estrogen Receptor Modulators (SERMs)

• Hormone Replacement Therapy

• Assisted Reproductive Technologies (ART)

The male hypogonadism market share offers therapies such as testosterone replacement therapy, selective estrogen receptor modulators (SERMs), hormone replacement therapy, and assisted reproductive technologies (ART). These therapies help to address the challenges associated with hypogonadism.

Market Breakup by Drug Delivery

• Topical Gels

• Injectables

• Transdermal Patches

• Others

The market for male hypogonadism is segmented by drug delivery methods into topical gels, injectables, transdermal patches, and others. This market segment represents diverse options available for administering testosterone replacement therapy and other treatment therapies.

Market Breakup by End User

• Hospitals and Clinics

• Specialty Clinics

• Retail Pharmacies

• Others

The male hypogonadism market report provides an insight into end users of the market as well. It includes hospitals and clinics, specialty clinics, retail pharmacies, and other healthcare facilities. This market segment includes diverse healthcare settings that provide treatment options for patients with male hypogonadism.

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

• China

Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and China. North America holds a high market value due to the rising cases of individuals with male hypogonadism. Furthermore, the rising awareness among patients and greater accessibility to treatment therapies are also driving the market demand.

Male Hypogonadism Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Lipocine Inc.

• Pfizer Inc

• AbbVie Inc

• Aytu BioPharma Inc.

• Merck & Co., Inc.

• Laboratoires Genevrier

• Ferring

• Perrigo Company plc

• Eli Lilly

• Bayer AG

• Endo International plc.

• Allergan plc

• Bristol-Myers Squibb Company

• AstraZeneca PLC

• IBSA Institute Bio Chimique SA

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Key Queries Solved in the Male Hypogonadism Market Report

• What is the projected growth of the male hypogonadism market over the forecast period?
• What are the primary factors driving the growth of the market?
• What are the main challenges or barriers hindering the growth of the market?
• What type of male hypogonadism will dominate the market share? 
• Which diagnostic method is expected to have a high market value in the coming years?
• Which drug delivery method will experience the highest demand in the market segment?
• What are the emerging trends and innovations in the market?
• What is the regulatory landscape governing the market?
• How does the prevalence of male hypogonadism impact the market growth?
• What are the current therapies available for male hypogonadism? Which therapy is expected to boost the male hypogonadism market value?
• How are healthcare expenditure patterns affecting the adoption of treatments for male hypogonadism?
• What is the competitive landscape of the male hypogonadism market, and who are the major players?
• What are the regional dynamics influencing the market growth?
• How are advancements in diagnostic technologies impacting the diagnosis and treatment of male hypogonadism?
• What are the key strategies adopted by market players?
• How are awareness campaigns affecting the diagnosis and treatment patterns related to male hypogonadism?